Allergan plc
Healthcare · Pharmaceutical Preparations · L2 · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | |
|---|---|---|---|---|---|---|
| Revenue | $3.60B | $3.67B | $15.94B | $14.57B | $12.69B | $4.68B |
| Operating income | −$4.45B | −$6.25B | −$5.92B | −$1.83B | −$3.13B | −$2.57B |
| Net income | −$5.27B | −$5.10B | −$4.13B | $14.97B | $3.92B | −$1.63B |
| Total assets | $94.70B | $101.79B | $118.34B | $128.99B | $135.58B | $52.76B |
| Total liabilities | $36.50B | $36.66B | $44.50B | $52.79B | $58.99B | $24.42B |
| Equity | $58.17B | $65.11B | $73.82B | $76.19B | $76.59B | $28.33B |
| EPS (diluted) | $-7.25 | $-0.99 | $-13.19 | $38.18 | $10.01 | $-7.42 |
| Shares out. | 332.6M | 330.3M | 335.2M | 394.7M | 266.3M | 174.2M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2019- Operating margin
- −123.6%
- Net margin
- −146.5%
- Return on equity
- −9.1%
- Return on assets
- −5.6%
- Return on capital (ROCE)
- −5.3%
- Liabilities / assets
- 38.5%
- Debt / equity
- 0.63×
- Book value / share
- $174.90
- Revenue growth (YoY)
- −2.0%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2019- Altman Z″ (distress)
- 1.40grey zone
- Accruals / assets
- −13.2%clean
- Beneish M-Score
- -3.04normal
- Piotroski F-Score
- 4/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 4 warning● 3 good- Operating losses (negative operating margin)
- Reported a net loss
- Revenue declined year-over-year
- Altman Z″ in the grey zone
- Conservative leverage (liabilities < 50% of assets)
- Positive operating cash flow
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
FDA-approved drugs
openFDA · most recent- TRETINOINOct 11, 2012
- GELNIQUE 3%Dec 7, 2011
- TRIVARISJun 16, 2008
- BYSTOLICDec 17, 2007
- SANCTURA XRAug 3, 2007
- NAMENDAApr 18, 2005
- SANCTURAMay 28, 2004
- ELESTATOct 16, 2003
Material events
SEC Form 8-K · most recent- Modified shareholder rightsMay 14, 2020
- Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylaws · Other material eventMay 8, 2020
- Other material eventMay 6, 2020
- Item 5.04 · Other material eventApr 21, 2020
- Other material eventMar 18, 2020
- Other material eventMar 3, 2020
- Results of operationsFeb 10, 2020
- Other material eventJan 27, 2020
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (5)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.